CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...